@article{b9123bf02e59444a9e166d991241315c,
title = "Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials",
keywords = "Quality of life, Responder, Schizophrenia, Trajectory, Yoga therapy",
author = "Saeko Ikai-Tani and Hideaki Tani and Saki Kamiyama and Masaru Mimura and Hiroyuki Uchida",
note = "Funding Information: Dr. Uchida has received grants from Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, Shionogi, Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; speaker{\textquoteright}s honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. ",
year = "2020",
month = dec,
doi = "10.1016/j.ajp.2020.102250",
language = "English",
volume = "54",
journal = "Asian Journal of Psychiatry",
issn = "1876-2018",
publisher = "Elsevier",
}
